Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Direct-to-Patient Platform

DxTerity has launched its Direct-to-Patient (D2P) platform for population-scale genomic studies. The D2P platform uses cost-effective, self-administered finger-stick blood collection and a nucleic acid stabilization device that can be distributed and returned via standard mail with no refrigeration required, the company said. The device stabilizes both the RNA and DNA in the blood sample enabling full genome and full transcriptome profiling. The sample, once returned, is analyzed in the company's CLIA-licensed, CAP-certified genomics laboratory. Electronic consent, electronic data capture, and electronic patient-reported outcomes are included in the D2P platform.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.